Refined crystal structures of native human angiogenin and two active site variants: Implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth

Journal of Molecular Biology

Volumn 285, Issue 3, 1999, Pages 1209-1233

  Leonidas, Demetres D ^a   Shapiro, Robert ^b   Allen, Simon C ^a   Subbarao, Gowtham V ^a   Veluraja, Kasinadar ^a   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Angiogenin; Nuclear translocation; Ribonuclease superfamily; X ray crystallography

Indexed keywords

ANGIOGENIN; ASPARTIC ACID; PYRIMIDINE; RIBONUCLEASE; RIBONUCLEASE A;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ARTICLE; BINDING SITE; CELL NUCLEUS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME STRUCTURE; EOSINOPHIL; HUMAN; HYDROGEN BOND; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR GROWTH;

BOVINAE;

EID: 0033593472     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2378     Document Type: Article

References (122)

1. Acharya K. R., Subramanian V., Shapiro R., Riordan J. F., Vallee B. L. Crystallization and preliminary X-ray analysis of human angiogenin. J. Mol. Biol. 228:1992;1269-1270.
2. Acharya K. R., Shapiro R., Allen S. C., Riordan J. F., Vallee B. L. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc. Natl Acad. Sci. USA. 91:1994;2915-2919.
3. Acharya K. R., Shapiro R., Riordan J. F., Vallee B. L. Crystal structure of bovine angiogenin at 1.5 Å resolution. Proc. Natl Acad. Sci. USA. 92:1995;2949-2953.
4. Acharya K. R., Leonidas D. D., Papageorgiou A. C., Russo N., Shapiro R. Structural studies on angiogenin, a protein implicated in neovascularization during tumour growth. Maragoudakis M. E. Angiogenesis, Models, Modulators, and Clinical Applications. 1998;165-178 Plenum Press, New York.
5. Ackerman S. J., Gleich G. J., Loegering D. A., Richardson B. A., Butterworth A. E. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of schistosoma-mansoni. Am. J. Trop. Med. Hyg. 34:1985;735-745.
6. Ardelt W., Lee H.-S., Randolph G., Viera A., Mikulski S. M., Shogen K. Enzymatic characterization of onconase, a novel ribonuclease with antitumor activity. Protein Sci. 3:1994;137.
7. Bicknell R., Vallee B. L. Angiogenin activates endothelial cell phospholipase C. Proc. Natl Acad. Sci. USA. 85:1988;2222-2226.
8. Bicknell R., Vallee B. L. Angiogenin stimulates endothelial-cell prostacyclin secretion by activation of phospholipase A2. Proc. Natl Acad. Sci. USA. 86:1989;1573-1577.
9. Boix E., Nogues M. V., Schein C. H., Benner S. A., Cuchillo C. M. Reverse transphosphorylation by ribonuclease A needs an intact (P2)- binding site. Point mutations at Lys 7 and Arg 10 alter the catalytic properties of the enzyme. J. Biol. Chem. 269:1994;2529-2534.
10. Boix E., Wu Y. N., Vasandani V. M., Saxena S. K., Ardelt W., Ladner J., Youle R. J. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J. Mol. Biol. 257:1996;992-1007.
11. Bond M. D., Strydom D. J., Vallee B. L. Characterization and sequencing of rabbit, pig and mouse angiogenins - discernment of functionally important residues and regions. Biochim. Biophys. Acta. 1162:1993;177-186.
12. Borah B., Chen C.-W., Egan W., Miler M., Wlodawer A., Cohen J. S. Nuclear magnetic resonance and neutron diffraction studies of the complex of ribonuclease A with uridine vanadate, a transition state analogue. Biochemistry. 24:1985;2058-2067.
13. Borkakoti N. The active site of ribonuclease A from the crystallographic studies of ribonuclease-A-inhibitor complexes. Eur. J. Biochem. 132:1983;89-94.
14. Borkakoti N., Moss D. A., Palmer R. A. Ribonuclease A: least squares refinement of structure at 1.45 Å resolution. Acta Crystallog. sect. B. 38:1982;2210-2217.
15. Brünger A. T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992a;472-475.
16. Brünger A. T. X-PLOR Version 3.1 Manual: A System for X-ray Crystallography & NMR. 1992b;Yale University Press, New Haven.
17. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
18. Cowtan K. Density modification package. Joint CCP4 ESF-EACBM Newsletter Protein Crystallog. 31:1994;34-38.
19. Curran T. P., Shapiro R., Riordan J. F. Alteration of the enzymatic specificity of human angiogenin by site directed mutagenesis. Biochemistry. 32:1993a;2307-2313.
20. Curran T. P., Shapiro R., Riordan J. F., Vallee B. L. Modulation of the activity of angiogenin by mutagenesis at Asp-116. Biochim. Biophys. Acta. 1202:1993b;281-286.
21. delCardayre S. B., Raines R. T. Structural determinants of enzymatic processivity. Biochemistry. 33:1994;6031-6037.
22. delCardayre S. B., Raines R. T. A residue to residue hydrogen bond mediates the nucleotide specificity of ribonuclease A. J. Mol. Biol. 252:1995;328-336.
23. delCardayre S. B., Ribó M., Yokel E. M., Quirk D. J., Rutter J., Raines R. T. Engineering ribonuclease A: production, purification and characterization of wild-type enzyme and mutants at Gln11. Protein Eng. 8:1995;261-273.
24. Dingwall C., Laskey R. Nuclear targeting sequences - a consensus? Trends Biochem. Sci. 16:1991;478-481.
25. Eberhardt E. S., Wittmayer P. K., Templer B. M., Raines R. T. Contribution of a tyrosine side-chain to ribonuclease A catalysis and stability. Protein Sci. 5:1996;1697-1703.
26. Esnouf R. M. An extensively modified version of MOLSCRIPT that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15:1997;132-134.
27. Fett J. W., Strydom D. J., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma-cells. Biochemistry. 24:1985;5480-5486.
28. Findlay D., Herries D. G., Mathias A. P., Rabin B. R., Ross C. A. The active site and mechanism of action of bovine pancreatic ribonuclease. Nature. 190:1962;781-785.
29. Fontecilla-Camps J. C., de Llorens R., le Du M. H., Cuchillo C. M. Crystal structure of ribonuclease A d(ApTpApAG) complex. J. Biol. Chem. 269:1994;21526-21531.
30. Gilliland G. L., Dill J., Pechik I., Svensson L. A., Sjolin L. The active site of bovine pancreatic ribonuclease: an example of solvent modulated specificity. Protein Pept. Letters. 1:1994;60-65.
31. Gleich G. J., Loegering D. A., Bell M. P., Checkel J. L., Ackerman S. J., McKean D. J. Biochemical and functional similarities between human eosinophil derived neurotoxin and eosinophil cationic protein - homology with ribonuclease. Proc. Natl Acad. Sci. USA. 83:1986;3146-3150.
32. Hallahan T. W., Shapiro R., Strydom D. J., Vallee B. L. Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry. 31:1992;12477-12485.
33. Hallahan T. W., Shapiro R., Vallee B. L. Dual site model for the organogenic activity of angiogenin. Proc. Natl Acad. Sci. USA. 88:1991;2222-2226.
34. Harper J. W., Vallee B. L. Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin. Proc. Natl Acad. Sci. USA. 85:1988;7139-7142.
35. Harper J. W., Vallee B. L. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis. Biochemistry. 28:1989;1875-1884.
36. Hodges R. S., Merrifield R. B. The role of serine-123 in the activity and specificity of ribonuclease. J. Biol. Chem. 250:1975;1231-1241.
37. Hu G.-f., Riordan J. F. Angiogenin enhances actin acceleration of plasminogen activation. Biochem. Biophys. Res. Commun. 197:1993;682-687.
38. Hu G.-f., Riordan J. F., Vallee B. L. Angiogenin promotes invasiveness of cultured endothelial-cells by stimulation of cell-associated proteolytic activities. Proc. Natl Acad. Sci. USA. 91:1994;12096-12100.
39. Hu G.-f., Chang S. I., Riordan J. F., Vallee B. L. An angiogenin-binding protein from endothelial cells. Proc. Natl Acad. Sci. USA. 88:1991;2227-2231.
40. Hu G.-f., Riordan J. F., Vallee B. L. A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc. Natl Acad. Sci. USA. 94:1997;2204-2209.
41. Hu G.-f., Strydom D. J., Fett J. W., Riordan J. F., Vallee B. L. Actin is a binding protein for angiogenin. Proc. Natl Acad. Sci. USA. 90:1993;1217-1221.
42. Irie M., Watanabe H., Ohgi K., Tobe M., Matsumura G., Arata Y., Hirose T., Inayama S. Some evidence suggesting the existence of P2 and B3 sites in active site of bovine pancreatic ribonuclease A. J. Biochem. 95:1984;751-759.
43. Jiang J.-S., Brünger A. T. Protein hydration observed by X-ray diffraction: solvation properties penicillopepsin and neuraminidase crystal structures. J. Mol. Biol. 243:1994;100-115.
44. Jimi S., Ito K., Kohno K., Ono M., Kuwano M., Itagaki Y., Ishikawa H. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem. Biophys. Res. Commun. 211:1995;476-483.
45. Jones T. A., Zou J. Y., Cowan S. W., Kjeldgaard M. Improved methods for building models in electron density maps & the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
46. Kabsch W. Evaluation of single crystal X-ray diffraction data from a position sensitive detector. J. Appl. Crystallog. 21:1988;916-924.
47. Kabsch W., Sanders C. Dictionary of the protein secondary structure: pattern recognition of hydrogen bonded and geometrical features. Biopolymers. 22:1983;2577-2637.
48. Kraulis P. J. MOLSCRIPT - a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
49. Kurachi K., Davie E. W., Strydom D. J., Riordan J. F., Vallee B. L. Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 24:1985;5494-5499.
50. Ladner J. E., Wladkoswki B. D., Svensson L. A., Sjolin L., Gilliland G. L. X-ray structure of a ribonuclease A-uridine complex at 1. 3 Å resolution. Acta Crystallog. sect. D. 53:1997;290-301.
51. Lee F. S., Shapiro R., Vallee B. L. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry. 28:1989;225-230.
52. Lee F. S., Vallee B. L. Binding of placental ribonuclease inhibitor to the active site of angiogenin. Biochemistry. 28:1989;3556-3561.
53. Leonidas D. D., Shapiro R., Irons L. I., Russo N., Acharya K. R. Crystal structures of ribonuclease A complexes with 5′-diphosphoadenosine 3′-phosphate and 5′-diphosphoadenosine 2′-phosphate at 1.7 Å resolution. Biochemistry. 36:1997;5578-5588.
54. 1H nuclear magnetic resonance spectroscopy. Biochemistry. 35:1996;8870-8880.
55. avalues. Eur. J. Biochem. 250:1997;712-726.
56. Lin M. C., Gutte B., Caldi D. G., Moore S., Merrifield R. B. Reactivation of des(119-124) ribonuclease A by mixture with synthetic COOH-terminal peptides; the role of phenylalanine-120. J. Biol. Chem. 247:1972;4768-4774.
57. Lisgarten J. N., Gupta V., Maes D., Wyns L., Zegers I., Palmer R. A., Dealwis C. G., Aguilar C. F., Hemmings A. M. Structure of the crystalline complex of cytidylic acid (2′-CMP) with ribo nuclease at 1.6 Å resolution. Conservation of solvent sites in RNase-A high resolution structures. Acta Crystallog. sect. D. 49:1993;541-547.
58. Ma P. C. M., Rould M. A., Weintraub H., Pabo C. O. Crystal structure of MyoD BHLH domain-DNA complex-perspectives on DNA recognition and implications for transcriptional activation. Cell. 77:1994;451-459.
59. Massiah M. A., Starich M. R., Paschall C., Summers M. F., Christensen A. M., Sundquist W. I. 3-Dimensional structure of the human immunodeficiency virus type-1 matrix protein. J. Mol. Biol. 244:1994;198-223.
60. Matoušek J. The effect of bovine seminal ribonuclease (BS RNase) on cells of Crocker tumours in mice. Experientia. 29:1973;858-859.
61. Mazzarella L., Capasso S., Demasi D., Di'Lorenzo G., Mattia C. A., Zagari A. Bovine seminal ribonuclease structure at 1.9 Å resolution. Acta Crystallog. sect. D. 49:1993;389-402.
62. McDonald I. K., Thornton J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238:1994;777-793.
63. Messmore J. M., Fuchs D. N., Raines R. T. Ribonuclease A: revealing structure-function relationships with semisynthesis. J. Am. Chem. Soc. 117:1995;8057-8060.
64. Mikulski S. M., Ardelt W., Shogen K., Bernstein E. H., Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J. Natl Cancer Inst. 82:1990;151-152.
65. Moroianu J., Riordan J. F. Identification of the nucleolar targeting signal of human angiogenin. Biochem. Biophys. Res. Commun. 203:1994a;1765-1772.
66. Moroianu J., Riordan J. F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl Acad. Sci. USA. 91:1994b;1677-1681.
67. Mosimann S. C., Ardelt W., James M. N. G. Refined 1.7 Å X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with antitumor activity. J. Mol. Biol. 236:1994;1141-1153.
68. Mosimann S. C., Newton D. L., Youle R. J., James M. N. G. X-ray crystallgraphic structure of recombinant eosinophil-derived neurotoxin at 1.83 Å resolution. J. Mol. Biol. 260:1996;540-552.
69. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallog. sect. A. 50:1994;157-163.
70. Neumann U., Hofsteenge J. Interaction of semisynthetic variants of RNase A with ribonuclease inhibitor. Protein Sci. 3:1994;248-256.
71. Newton D. L., Walbridge S., Mikulski S. M., Ardelt W., Shogen K., Ackerman S. J., Rybak S. M., Youle R. J. Toxicity of an antitumor ribonuclease to Purkinje neurons. J. Neurosci. 14:1994;538-544.
72. Nobile V., Russo N., Hu G.-f., Riordan J. F. Inhibition of human angiogenin by DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex. Biochemistry. 37:1998;6857-6863.
73. Nobile V., Vallee B. L., Shapiro R. Characterization of mouse angiogenin-related protein - implications for functional studies on angiogenin. Proc. Natl Acad. Sci. USA. 93:1996;4331-4335.
74. Nogues M. V., Vilanova M., Cuchillo C. M. Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. Biochim. Biophys. Acta. 1253:1995;16-24.
75. Olson K. A., Fett J. W. Prostatic carcinoma therapy with angiogenin antagonists. Proc. Am. Assoc. Cancer Res. 37:1996;57.
76. Olson K. A., Fett J. W. Inhibition of tumour growth and metastasis by angiogenin antisense therapy. Proc. Am. Assoc. Cancer Res. 39:1998;98.
77. Olson K. A., Fett J. W., French T. C., Key M. E., Vallee B. L. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl Acad. Sci. USA. 92:1995;442-446.
78. Olson K. A., French T. C., Vallee B. L., Fett J. W. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54:1994;4576-4579.
79. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Carter C. W. J., Sweet R. M. Methods in Enzymology. 1997;307-326 Academic Press, New York.
80. Papageorgiou A. C., Shapiro R., Acharya K. R. Molecular recognition of human angiogenin by placental ribonuclease inhibitor-an X-ray crystallographic study at 2.0 Å resolution. EMBO J. 17:1997;5162-5177.
81. Parés X., Nogués M. V., Llorens R., Cuchillo C. M. Structure and function of ribonuclease A binding subsites. Essays Biochem. 26:1991;89-103.
82. Prieve M. G., Guttridge K. L., Munguia J. E., Waterman M. L. The Nuclear-localization signal of lymphoid enhancer factor-I is recognized by 2 differentially expressed SRP-1 nuclear localization sequence receptor proteins. J. Biol. Chem. 271:1996;7654-7658.
83. Raines R. T. Ribonuclease A. Chem. Rev. 98:1998;1045-1065.
84. Read J. Improved fourier coefficient for maps using phases from partial structures with errors. Acta Crystallog. sect. A. 42:1986;140-149.
85. Richards F. M., Wyckoff H. W. Bovine pancreatic ribonuclease. The Enzymes. 1971;. p. 647-806.
86. Richards F. M., Wyckoff H. W. Ribonuclease S. Phillips D. C., Richards F. M. Atlas of Molecular Structures in Biology. 1973;2-73 Clarendon Press, Oxford.
87. Richardson R. M., Pares X., Llorens R., Nogues M. V., Cuchillo C. M. Nucleotide binding and affinity labeling support the existence of the phosphate-binding subsite P2 in bovine pancreatic ribonuclease A. Biochim. Biophys. Acta. 953:1988;70-78.
88. Russo N., Acharya K. R., Vallee B. L., Shapiro R. A combined kinetic and modelling study of the catalytic center subsites of human angiogenin. Proc. Natl Acad. Sci. USA. 93:1996a;804-808.
89. Russo N., Nobile V., DiDonato A., Riordan J. F., Vallee B. L. The C-terminal region of human angiogenin has a dual role in enzymatic activity. Proc. Natl Acad. Sci. USA. 93:1996b;3243-3247.
90. Russo N., Shapiro R., Acharya K. R., Riordan J. F., Vallee B. L. Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. Proc. Natl Acad. Sci. USA. 91:1994;2920-2924.
91. Russo N., Shapiro R., Vallee B. L. 5′-Diphosphoadenosine 3′-phosphate is a potent inhibitor of bovine pancreatic ribonuclease A. Biochem. Biophys. Res. Commun. 231:1997;671-674.
92. Rybak S. M., Vallee B. L. Base cleavage specificity of angiogenin with Saccharomyces cerevisiae and Escherichia coli. 5S-RNAs. Biochemistry. 27:1988;2288-2294.
93. Schultz L. W., Quirk D., Raines R. T. His - Asp catalytic dyad of ribonuclease A: structure and function of the wild-type, D121N, and D121A enzymes. Biochemistry. 37:1998;8886-8898.
94. Shapiro R. Structural features that determine the enzymatic potency and specificity of human angiogenin: Thr-80 and residues 58-70 and 116-123. Biochemistry. 37:1998;6847-6856.
95. Shapiro R., Fox E. A., Riordan J. F. Role of lysines in human angiogenin - chemical modification and site-directed mutagenesis. Biochemistry. 28:1989;1726-1732.
96. Shapiro R., Harper J. W., Fox E. A., Jansen H. W., Hein F., Uhlmann E. Expression of Met-(-1) angiogenin in Escherichia coli.- conversion to the authentic
97. Shapiro R., Strydom D. J., Weremowicz S., Vallee B. L. Sites of modification of human angiogenin by bromoacetate at pH 5.5. Biochem. Biophys. Res. Commun. 156:1988b;530-536.
98. Shapiro R., Riordan J. F., Vallee B. L. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 25:1986;3527-3532.
99. Shapiro R., Vallee B. L. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin - alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 28:1989;7401-7408.
100. Shapiro R., Vallee B. L. Interaction of human placental ribonuclease with placental ribonuclease inhibitor. Biochemistry. 30:1991;2246-2255.
101. Shapiro R., Vallee B. L. Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry. 31:1992;12477-12485.
102. Shapiro R., Weremowicz S., Riordan J. F., Vallee B. L. Ribonucleolytic activity of angiogenin - essential histidine, lysine, and arginine residues. Proc. Natl Acad. Sci. USA. 84:1987;8783-8787.
103. Sivaraja M., Botfield M. C., Mueller M., Jancso A., Weiss M. A. Solution structure of a π-specific homeodomain - 3D-NMR studies of human B-cell transcription factor OCT-2. Biochemistry. 33:1994;9845-9855.
104. Slifman N. R., Leogering D. A., McKean D. J., Gleich G. J. Ribonuclease-activity associated with human eosinophil derived neurotoxin and eosinophil cationic protein. J. Immunol. 137:1986;2913-2917.
105. Sock E., Enderich J., Rosenfeld M. G., Wegner M. Identification of the nuclear-localization signal of the π domain protein TST-1/OCT6. J. Biol. Chem. 271:1996;17512-17518.
106. Sorrentino S., D. G. G., Hamann K. J., Loegering D. A., Checkel J. L., Gleich G. L. Eosinophil-derived neurotoxin and human liver ribonuclease - identity of structure and linkage of neurotoxicity to nuclease activity. J. Biol. Chem. 267:1992;14859-14865.
107. Sorrentino S., Tucker G. K., Glitz D. G. Purification and characterization of a ribonuclease from human-liver. J. Biol. Chem. 263:1988;16125-16131.
108. Soucek J., Chudomel V., Potmesilova I., Novak J. T. Effect of ribonucleases on cell-mediated lympholysis reaction and on Gm-Cfc colonies in bone-marrow culture. Nat. Immun. Cell Growth Regul. 5:1986;250-258.
109. Strydom D. J., Bond M. D., Vallee B. L. An angiogenic protein from bovine serum and milk - purification and primary structure of angiogenin-2. Eur. J. Biochem. 247:1997;535-544.
110. Strydom D. J., Fett J. W., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Amino-acid sequence of human-tumor derived angiogenin. Biochemistry. 24:1985;5486-5494.
111. Stuart D. I., Levine M., Muirhead H., Stammers D. K. The catalytic structure of cat pyruvate kinase at a resolution of 2.6 Å J. Mol. Biol. 134:1979;109-142.
112. Tarragona-Fiol A., Eggelte H. J., Harbron S., Sanchez E., Taylorson C. J., Ward J. M., Rabin B. R. Identification by site-directed mutagenesis of amino-acids in the B2 subsite of bovine pancreatic ribonuclease A. Protein Eng. 6:1993;901-906.
113. Thompson J. E., Raines R. T. Value of general acid-base catalysis to ribonuclease A. J. Am. Chem. Soc. 116:1994;5467-5468.
114. Toiron C., Gonzalez C., Bruix M., Rico M. Three-dimensional structure of the complexes of ribonuclease A with 2′,5′-CpA and 3′,5′-d(CpA) in aqueous solution, as obtained by NMR and restrained molecular dynamics. Protein Sci. 5:1996;1633-1647.
115. Trautwein K. P., Holliger P., Stackhouse J., Benner S. A. Site-directed mutagenesis of bovine pancreatic ribonuclease. Lysine-41 and aspartate-121. FEBS Letters. 281:1991;275-277.
116. Witzel H., Barnard E. A. Mechanism and binding sites in the ribonuclease reaction II. Kinetic studies on the first step of the reaction. Biochem. Biophys. Res. Commun. 7:1962;295-299.
117. Wladkowski B. D., Svensson L. A., Sjolin L., Ladner J. E., Gilliland G. L. Structure (1.3 Å) and charge states of a ribonuclease A-uridine vanadate complex: implications for the phosphate ester hydrolysis mechanism. J. Am. Chem. Soc. 120:1998;5488-5498.
118. Wlodawer A., Miller M., Sjolin L. Active site of RNase:neutron diffraction study of a complex with uridine vanadate, a transition state analog. Proc. Natl Acad. Sci. USA. 80:1983;3628-3631.
119. Wlodawer A., Svensson L. A., Sjolin L., Gilliland G. L. Structure of phosphate-free ribonuclease A refined at 1.26 Å Biochemistry. 27:1988;2705-2717.
120. Wodak S. Y., Liu M. Y., Wyckoff H. W. The structure of cytidilyl (2′,5′) adenosine when bound to pancreatic ribonuclease S. J. Mol. Biol. 116:1977;855-875.
121. Wu Y.-N., Mikulski S. M., Ardelt W., Rybak S. M., Youle R. J. A cytotoxic ribonuclease: study of the mechanism of onconase cytotoxicity. J. Biol. Chem. 268:1993;10686-10693.
122. Zegers I., Maes D., Dao-Thi M.-H., Poortmans F., Palmer R., Wyns L. The structures of RNase A complexed with 3′-CMP and d(CpA): active site conformation and conserved water molecules. Protein Sci. 31:1994;2322-2339.